EP Patent

EP1912625A2 — Itraconazole compositions with improved bioavailability

Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2008-04-23 · 18y expired

What this patent protects

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailabi…

USPTO Abstract

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.

Drugs covered by this patent

Patent Metadata

Patent number
EP1912625A2
Jurisdiction
EP
Classification
—
Expires
2008-04-23
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Deutschland GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.